NEXENTIS TECHNOLOGIES INC.

NXTS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $210.0K $263.4K $394.0K $438.1K $232.3K $175.8K $426.6K
Cost of Revenue $165.0K $55.0K $158.3K $135.9K $43.4K $144.5K $111.1K
Gross Profit $45.0K $208.0K $235.7K $302.2K $188.9K $31.3K $315.5K
Gross Margin 21.4% 79.0% 59.8% 69.0% 81.3% 17.8% 74.0%
Operating Expenses
Research & Development $369.0K $1.9M $770.8K $538.7K $417.0K $615.6K $357.1K
SG&A Expense $3.3M $5.6M $4.7M $4.3M $1.1M $1.0M $336.4K
Operating Income $-3.3M $-7.6M $-5.8M $-4.7M $-1.3M $-1.9M $-518.7K
Operating Margin -1,563.3% -2,876.5% -1,477.1% -1,073.5% -580.9% -1,098.4% -121.6%
Interest Expense $16
Pretax Income $-4.3M
Income Tax Expense
Net Income $-5.2M $-6.5M $-5.7M $-4.8M $-1.6M $-2.0M $-356.9K
Net Margin -2,472.9% -2,475.7% -1,456.7% -1,100.2% -685.9% -1,121.3% -83.7%
EPS (Basic) $-3.96 $-0.78 $0.78 $-0.15 $-0.08 $-0.10 $0.00
EPS (Diluted) $-3.96 $-0.78 $0.78 $-0.15 $-0.08 $-0.10 $0.00
Shares Outstanding (Basic) 1.3M 8.4M 7.4M 32.8M 21.3M 19.9M 93.3M
Shares Outstanding (Diluted) 1.3M 8.4M 7.4M 32.8M 21.3M 19.9M 93.3M
Dividends Per Share